The research builds on foundational LDL receptor work by UT Southwestern researchers Michael Brown and Joseph Goldstein and aligns with prior PCSK9 inhibitor developments like evolocumab and alirocumab.

Enlicitide advances decades of cholesterol research on LDL receptor and PCSK9 pathways and moves from injectable therapies toward an oral formulation.

The daily oral formulation could improve adherence and broaden access, addressing some barriers associated with injections and coverage for PCSK9-targeted therapy.

The study was sponsored by Merck & Co., with disclosures noting consulting fees related to Merck and other lipid-lowering drug makers, highlighting potential conflicts of interest.

The trial enrolled 2,909 participants with atherosclerosis or high cardiovascular risk; about two-thirds received enlicitide and one-third received placebo, with most participants already on statins and a baseline LDL around 96 mg/dL.

If ongoing trials confirm reductions in cardiovascular events beyond lipid lowering, enlicitide could become a major advance in lipid management and cardiovascular prevention.

Some authors are affiliated with UT Southwestern Medical Center, and disclosures include consulting fees related to Merck and other lipid-lowering products.

After 24 weeks, enlicitide achieved roughly a 60% LDL reduction versus placebo, with improvements in non-HDL cholesterol and apolipoprotein B, sustained for one year.

Enlicitide, an experimental oral drug, reduced LDL cholesterol by up to about 60% in a phase III trial, signaling a potential new therapy to prevent heart attacks and strokes if approved by the FDA.

A follow-up trial is underway to determine if the LDL reductions translate into fewer cardiovascular events, such as heart attacks and strokes.

The study highlights ongoing challenges in achieving LDL targets for high-risk patients, noting that even high-intensity statin therapy often falls short.

Enlicitide targets the PCSK9 pathway and is taken orally once daily, offering a potentially simpler option compared with injectable PCSK9 inhibitors.